The global plasma fractionation market size is projected to reach USD 40.4 billion by 2028 from USD 29.0 billion in 2023, at a CAGR of 6.9% during the forecast period. The growing popularity of immunoglobulins for the treatment of various therapeutic areas such as hematology, neurology, and pulmonology, as well as the use of protease inhibitors for the treatment of lung and hepatic disorders with rising incidence rates, are driving the growth of the market. However, the rising cost of plasma-derived products, limited reimbursements, and the rise of recombinant alternatives are projected to hamper the market's growth during the forecast period.
The global plasma fractionation market is highly consolidated. The prominent players operating in this market include CSL (Australia), Takeda Pharmaceutical company limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), ADMA Biologics (US), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Hualan Bioengineering Co., Ltd. (China), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Kamada (Israel), Centurion Pharma (Istanbul), Prothya Biosolutions (Netherlands), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India). Geographic expansions and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.
To know about the assumptions considered for the study download the pdf brochure
In 2022, CSL dominated the plasma fractionation market with a share of 27–30%. CSL has established itself as a prominent participant in the plasma fractionation industry, with distribution channels in more than 40 countries and 230 plasma collection facilities. The company offers plasma-derived medicines for both acute and chronic diseases such as hemophilia, von Willebrand disease, and primary immunological deficiencies.
The company is well-established in North America, Asia, Australia, and Europe. Its distribution network spans 30 nations, including major centers in Australia, Germany, Switzerland, and the United States. This enables the company to ensure that its products are available globally.
Continuous research and development initiatives have enabled the company to emerge as a potent competitor to top plasma fractionation product providers. In the last five years, the company invested around USD 3.3 billion to develop and deliver innovative biotherapies; it has more than 1,700 employees dedicated to R&D activities. The company focuses on strategies such as expansions to enhance its presence in the market. In March 2023, the company announced the opening of a USD 470 million Plasma Fractionation Facility in Marburg, Germany.
However, the company's legal issues and a decline in its liquidity ratio might limit its expansion to some extent. In the coming years, stringent regulations from the government and unfavorable currency exchange rates can also have an impact on the company's growth.
Takeda Pharmaceutical Company Limited accounted for a share of 19–21% of the plasma fractionation market in 2022. In 2019, Shire was acquired by Takeda. The company's market position is owed to its expertise in medical devices, pharmaceuticals, and biotechnology. BioLife, a subsidiary of Takeda, is a global plasma collection network for high-quality plasma. In order to boost production, Takeda Pharmaceutical Company Limited also operates more than 80 plasma collection facilities in 24 US states and 7 locations in Austria. In order to meet the growing demand for its plasma-based medicines and to remain competitive in the plasma fractionation industry, the company also maintains relations with other plasma providers. For instance, it signed a ten-year contract manufacturing agreement with the Netherlands-based Sanquin Blood Supply Foundation. Such partnerships between two leading pharmaceutical companies fuel a company's market dominance.
Grifols accounted for a share of 17–19% of the plasma fractionation market in 2022. Grifols is a global healthcare company that develops, manufactures, and distributes plasma-derived products. To maintain its position in the market, the company concentrates on product innovation and research. Grifols invests extensively in research and development and collaborates with research institutes to produce innovative plasma-derived products to combat rare diseases. In addition, the company is continually expanding its plasma collection centers and boosting its capacity. It has 35 locations in Europe and more than 190 in the US. The company purchased 24 plasma collection facilities from Biotest US Corporation in August 2018. The company also engages with patients to create awareness and provide support. In September 2022, the company signed an agreement with Canadian Blood Services, Canada's national blood authority, to significantly increase the country's self-sufficiency in immunoglobulin (Ig) medicines. The company also constantly focuses on expanding its plasma collection centers and increasing its capacity. It has more than 190 centers in the US and 35 in Europe.
Octapharma AG accounted for 10–12% of the plasma fractionation market in 2022. Octapharma engages in research to improve existing products and to discover novel therapeutic applications for human protein products produced from human blood plasma and human cell lines. The company focuses on both organic and inorganic growth strategies, including partnerships, product launches, and expansions. In a collaboration formed by CSL (Australia), Takeda (Japan), BPL (UK), Biotest (Germany), and LFB (France) in April 2020, the company joined efforts to create a potential plasma-derived hyperimmune immunoglobulin therapy for COVID-19. The company focuses on using a variety of marketing techniques to build brand recognition in the plasma fractionation sector in order to maintain its presence. Since 2018, the company has received seven approvals from various regulatory bodies for its products.
Kedrion accounted for 2–4% of the plasma fractionation market in 2022. The company has 24 plasma collecting facilities worldwide and a significant presence in approximately 100 countries in Asia, Europe, North America, and Latin America. Kedrion's main growth strategy is collaboration and agreements. In order to develop, produce, and distribute a human plasma-derived Anti-SARS-COV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential cure for coronavirus patients, the company partnered with Kamada Ltd. (Israel) in April 2020. In addition, the company collaborates with several hemophilia institutions to give long-term access to hemophilia therapy through donating plasma-derived products to developing and European nations that do not satisfy the basic hemophilia care criteria. In January 2022, LFB and Kedrion signed an agreement in which Kedrion would manufacture immunoglobulins in Hungary from LFB’s plasma collected in France by the Établissement Français du Sang. Such initiatives by Kedrion help the company gain a competitive edge in the market.
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE